how big is Thyrocare Tech.?

As of Jun 06, Thyrocare Technologies Ltd has a market capitalization of 5,048.42 Cr, with recent net sales of 687.35 Cr and a net profit of 91.65 Cr over the latest four quarters. Shareholder's funds are 526.77 Cr, and total assets amount to 629.06 Cr as of Mar'24.

Market Cap: As of Jun 06, Thyrocare Technologies Ltd has a market capitalization of 5,048.42 Cr, categorizing it as a Mid Cap company.<BR><BR>Recent Quarterly Performance: For the latest 4 quarters, the sum of Net Sales is 687.35 Cr, and the sum of Net Profit is 91.65 Cr. This data is presented on a Consolidated basis.<BR><BR>Balance Sheet Snapshot: This is also on a Consolidated basis for the latest annual period ending in Mar'24. Shareholder's Funds are reported at 526.77 Cr, while Total Assets amount to 629.06 Cr.

Who are in the management team of Thyrocare Tech.?

As of March 2022, the management team of Thyrocare Tech includes Rahul Guha (Managing Director & CEO), along with several independent and non-independent directors, such as Ramjee Dorai (Company Secretary) and Gopal Shivram Hegde. The team features a diverse mix of roles to oversee the company's operations.

As of March 2022, the management team of Thyrocare Tech includes the following individuals:<BR><BR>1. **Rahul Guha** - Managing Director & CEO<BR>2. **Ramjee Dorai** - Company Secretary & Compliance Officer<BR>3. **Gopal Shivram Hegde** - Independent Director<BR>4. **Neetin Shivajirao Desai** - Independent Director<BR>5. **Vishwas Madhav Kulkarni** - Independent Director<BR>6. **Indumati Gopinathan** - Independent Director<BR>7. **Dhaval Shah** - Non-Executive & Non-Independent Director<BR>8. **Dharmil Sheth** - Non-Executive & Non-Independent Director<BR>9. **Hardik Dedhia** - Non-Executive & Non-Independent Director<BR>10. **Prapti Ishwar Gilada** - Independent Director<BR>11. **Harshil Jiten Vora** - Independent Director<BR><BR>This team comprises a mix of independent and non-independent directors, along with key executive roles.

Who are the peers of the Thyrocare Tech.?

Thyrocare Tech.'s peers include Syngene Intl., Dr Lal Pathlabs, and Krsnaa Diagnost., among others. In terms of management risk, growth, and capital structure, Thyrocare Tech. is rated as having good management risk and capital structure, with a 1-year return of 67.17%.

Peers: The peers of Thyrocare Tech. are Syngene Intl., Dr Lal Pathlabs, Poly Medicure, Indegene, Vijaya Diagnost., Suven Life Scie., Vimta Labs, Laxmi Dental, Krsnaa Diagnost., and Tarsons Products.<BR><BR>Quality Snapshot: Excellent management risk is observed at Dr Lal Pathlabs and Laxmi Dental, while Good management risk is found at Syngene Intl., Poly Medicure, Indegene, Vijaya Diagnost., and Thyrocare Tech. Average management risk is noted at Vimta Labs and Krsnaa Diagnost., and Below Average management risk is seen at Suven Life Scie. and Tarsons Products. Growth ratings show that Excellent growth is found at Vimta Labs, while Average growth is observed at Poly Medicure and Indegene, and Below Average growth is noted at Syngene Intl., Dr Lal Pathlabs, Vijaya Diagnost., Thyrocare Tech., and Krsnaa Diagnost. The rest have Below Average growth. Excellent capital structure is present at Syngene Intl., Dr Lal Pathlabs, Poly Medicure, Indegene, Vijaya Diagnost., Thyrocare Tech., and Krsnaa Diagnost., while Good capital structure is seen at Laxmi Dental, and Below Average capital structure is noted at Suven Life Scie.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Suven Life Scie. at 160.99%, while the lowest is Syngene Intl. at -3.51%. Thyrocare Tech.'s 1-year return of 67.17% is significantly higher than that of Syngene Intl. Additionally, Krsnaa Diagnost. and Tarsons Products have negative six-month returns.

Is Thyrocare Tech. overvalued or undervalued?

As of July 3, 2025, Thyrocare Technologies is considered very expensive and overvalued due to its high PE ratio of 59.09, Price to Book Value of 9.91, and EV to EBITDA of 27.57, despite a strong ROCE of 35.59% and a one-year stock return of 59.53%.

As of 3 July 2025, the valuation grade for Thyrocare Technologies has moved from expensive to very expensive, indicating a significant concern regarding its current pricing. The company is deemed overvalued based on its high PE ratio of 59.09, a Price to Book Value of 9.91, and an EV to EBITDA of 27.57. These ratios suggest that investors are paying a premium for the stock relative to its earnings and book value.<BR><BR>In comparison to its peers, Thyrocare's valuation appears excessive, especially when looking at Max Healthcare, which has a PE of 112.13, and Apollo Hospitals with a PE of 75.12. While Thyrocare's ROCE stands at a robust 35.59%, the high PEG ratio of 2.01 further emphasizes the overvaluation concern. Additionally, despite a strong one-year stock return of 59.53% compared to the Sensex's 4.07%, the elevated valuation metrics suggest that the stock may not sustain this growth, reinforcing the conclusion that Thyrocare Technologies is overvalued.

What does Thyrocare Tech. do?

Thyrocare Technologies Ltd provides affordable diagnostic services in the healthcare sector, with recent net sales of ₹1,872 Cr and a net profit of ₹217 Cr as of March 2025. The company has a market cap of ₹6,131 Cr and key metrics include a P/E ratio of 69.00 and a dividend yield of 1.54%.

Overview:<BR>Thyrocare Technologies Ltd operates in the healthcare services industry, providing quality diagnostic services at affordable costs.<BR><BR>History:<BR>The company was incorporated in January 2000 and continues to operate in the healthcare sector. The latest quarterly results reported net sales and net profit for the period ending March 2025.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 1,872 Cr (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: 217 Cr (Quarterly Results - Mar 2025) <BR>Market-cap value: INR 6,131 Cr (Mid Cap)<BR><BR>Key Metrics:<BR>P/E: 69.00 <BR>Industry P/E: 59 <BR>Dividend Yield: 1.54% <BR>Debt-Equity: -0.31 <BR>Return on Equity: 16.76% <BR>Price to Book: 11.32 <BR><BR>Contact Details:<BR>Address: D-37/1 TTC Industrial Area, MIDC Turbhe Navi Mumbai Maharashtra : 400703 <BR>Tel: 91-22-27622762 <BR>Email: investor_relations@thyrocare.com <BR>Website: http://www.thyrocare.com

Who are the top shareholders of the Thyrocare Tech.?

The top shareholder of Thyrocare Technologies is Docon Technologies Private Limited, holding 71.06%. Other significant shareholders include Nippon Life India Trustee Ltd at 7.05%, mutual funds with 12.97%, foreign institutional investors at 2.41%, and individual investors with 9.21%.

The top shareholders of Thyrocare Technologies include a mix of promoters, mutual funds, and individual investors. The majority shareholder is Docon Technologies Private Limited, which holds a significant 71.06% of the company. Promoters collectively have pledged their holdings entirely. Among public shareholders, Nippon Life India Trustee Ltd, representing the Nippon India Small Cap Fund, is the largest with a holding of 7.05%. Additionally, mutual funds account for 12.97% of the shares, held by seven different schemes, while foreign institutional investors (FIIs) hold 2.41%. Individual investors collectively own 9.21% of the company.

Are Thyrocare Tech. latest results good or bad?

Thyrocare Technologies reported strong financial results for June 2025, with a 53.07% increase in Profit Before Tax and a record high net sales growth of 23.02%, indicating a solid performance overall. Therefore, the latest results can be considered good, reflecting significant growth and profitability.

Thyrocare Technologies has reported strong financial results for the quarter ending June 2025, indicating a positive performance overall. The company achieved a Profit Before Tax (PBT) of Rs 45.83 crore, which is a significant year-on-year growth of 53.07%. Profit After Tax (PAT) also saw a robust increase, reaching Rs 38.93 crore, up by 61.1% compared to the previous year.<BR><BR>Net sales hit a record high of Rs 193.03 crore, reflecting a 23.02% growth year-on-year, the highest growth rate in the last five quarters. Additionally, the Operating Profit (PBDIT) reached Rs 57.77 crore, further highlighting the company's strong operational performance. Earnings per Share (EPS) increased to Rs 7.35, marking the highest level in recent quarters.<BR><BR>While there was a rise in non-operating income, which may not be sustainable, the overall financial metrics suggest that Thyrocare Technologies is in a solid position within the healthcare services sector. Therefore, the latest results can be considered good, showcasing significant growth and profitability.

When is the next results date for Thyrocare Tech.?

Thyrocare Tech. will announce its results on 14 October 2025.

Thyrocare Tech. will declare its results on 14 October 2025.

Has Thyrocare Tech. declared dividend?

Yes, Thyrocare Technologies Ltd has declared a 70% dividend, amounting to ₹21 per share, with an ex-date of July 25, 2025. The company has demonstrated strong total returns across various periods, reflecting its commitment to shareholder value.

Thyrocare Technologies Ltd has declared a 70% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 70%<BR>- Amount per share: 21<BR>- Ex-date: Jul-25-2025<BR><BR>Dividend Yield: 1.69%.<BR><BR>Total Returns by Period:<BR>In the last 3 months, the price return was 6.28%, the dividend return was 2.37%, resulting in a total return of 8.65%.<BR><BR>Over the past 6 months, the price return reached 79.35%, with a dividend return of 3.81%, culminating in a total return of 83.16%.<BR><BR>For the 1-year period, the price return was 43.61%, the dividend return was 3.11%, leading to a total return of 46.72%.<BR><BR>In the 2-year span, the price return stood at 123.52%, with a dividend return of 8.53%, resulting in a total return of 132.05%.<BR><BR>Over the last 3 years, the price return was 89.03%, the dividend return was 9.93%, giving a total return of 98.96%.<BR><BR>In the 4-year period, the price return was 11.77%, with a dividend return of 6.78%, resulting in a total return of 18.55%.<BR><BR>Finally, in the 5-year period, the price return was 25.73%, the dividend return was 9.86%, leading to a total return of 35.59%.<BR><BR>Overall, Thyrocare Technologies Ltd has shown a strong performance with significant total returns across various periods, supported by a declared dividend, indicating a commitment to returning value to shareholders.

Should I buy, sell or hold Thyrocare Tech.?

How has been the historical performance of Thyrocare Tech.?

Thyrocare Tech. has shown steady growth in net sales and profits, with net sales increasing from 402.91 Cr in Mar'19 to 687.35 Cr in Mar'25, and profit after tax rising to 92.19 Cr in Mar'25. The company has demonstrated resilience with improved earnings per share and strong cash flow from operating activities.

Answer:<BR>The historical performance of Thyrocare Tech. shows a steady growth in net sales and profits over the years, with a notable increase in recent years.<BR><BR>Breakdown:<BR>Thyrocare Tech. has demonstrated a consistent upward trend in net sales, rising from 402.91 Cr in Mar'19 to 687.35 Cr in Mar'25. Total operating income followed a similar trajectory, reaching 687.35 Cr in Mar'25, up from 571.88 Cr in Mar'24. The company's total expenditure also increased, amounting to 496.99 Cr in Mar'25 compared to 434.45 Cr in Mar'24. Operating profit, however, saw fluctuations, peaking at 264.14 Cr in Mar'22 before declining to 205.19 Cr in Mar'25. Profit before tax increased to 146.88 Cr in Mar'25 from 95.59 Cr in Mar'24, while profit after tax rose to 92.19 Cr in Mar'25, up from 69.10 Cr in Mar'24. The earnings per share (EPS) improved to 17.27 in Mar'25 from 13.36 in Mar'24. On the balance sheet, total assets grew to 684.22 Cr in Mar'25 from 629.06 Cr in Mar'24, while total liabilities also increased to 684.22 Cr in Mar'25. Cash flow from operating activities showed a positive trend, reaching 191 Cr in Mar'25, indicating strong operational performance. Overall, Thyrocare Tech. has shown resilience and growth in its financial metrics over the years.

What is the bonus history of Thyrocare Tech.?

Thyrocare Technologies Ltd recently announced a 2:1 bonus issue, with an ex-date of November 28, 2025. Shareholders will receive two additional shares for every one share held as of that date.

Thyrocare Technologies Ltd has a recent bonus issue where they announced a 2:1 bonus. The ex-date for this bonus is set for November 28, 2025. This means that shareholders will receive two additional shares for every one share they hold as of the record date, which is also November 28, 2025. If you have any further questions about Thyrocare or its corporate actions, feel free to ask!

Is Thyrocare Tech. technically bullish or bearish?

As of December 2, 2025, Thyrocare Tech. shows a mildly bullish trend supported by bullish MACD and moving averages, but tempered by a mildly bearish KST and Dow Theory signals, indicating caution in the current market.

As of 2 December 2025, the technical trend for Thyrocare Tech. has changed from bullish to mildly bullish. The current stance is mildly bullish, supported by a bullish MACD on both weekly and monthly time frames, and daily moving averages indicating bullish momentum. However, the KST shows a mildly bearish signal on the weekly chart, which tempers the overall bullish outlook. Bollinger Bands are also indicating mildly bullish conditions on both weekly and monthly charts. The RSI shows no significant signals, and Dow Theory reflects a mildly bearish stance on the weekly chart with no trend on the monthly. Overall, while there are bullish indicators present, the mildly bearish signals suggest caution in the current market environment.

Which are the latest news on Thyrocare Tech.?

Why is Thyrocare Tech. falling/rising?

As of 13-Dec, Thyrocare Technologies Ltd's stock price is at 434.65, down slightly by 0.03%. Despite a strong long-term performance with a year-to-date increase of 44.31%, current challenges include underperformance relative to its sector, declining investor participation, and concerns over long-term growth and high promoter share pledges.

As of 13-Dec, Thyrocare Technologies Ltd's stock price is currently at 434.65, reflecting a slight decrease of 0.15 (-0.03%). Despite this minor decline, the stock has shown strong performance over the longer term, with a year-to-date increase of 44.31% and a one-year return of 32.91%, significantly outperforming the Sensex, which has only increased by 9.12% over the same period.<BR><BR>However, the stock is facing some challenges that may contribute to its current price movement. Today, it underperformed its sector by 0.96%, indicating weaker performance relative to its peers. Additionally, there has been a notable decline in investor participation, with delivery volume dropping by 62.87% compared to the five-day average, which could signal reduced interest from investors.<BR><BR>While the company has demonstrated high management efficiency and strong financial results, including a net profit growth of 77.95% and positive results for the last seven consecutive quarters, concerns about its long-term growth persist. The annual growth rates for net sales and operating profit over the last five years are relatively modest at 12.85% and 8.89%, respectively. Furthermore, the stock is trading at a premium valuation compared to its peers, which may deter some investors.<BR><BR>Another factor weighing on the stock is the high percentage of promoter shares pledged, at 85.84%. In a declining market, this can exert additional downward pressure on the stock price. Overall, while Thyrocare Technologies Ltd has shown impressive long-term performance, current market conditions and investor sentiment appear to be contributing to its recent price decline.